Ottawa, Ontario--(Newsfile Corp.-November 23, 2021)-Innovative Medicines Canada (IMC) is pleased to announce that Cole C. Pinnow, President of Pfizer Canada ULC, has been selected as Chairman of the Board of Directors.
“Cole has worked tirelessly with IMC’s outgoing chairman Ronnie Miller for the past two years, bringing together IMC members, governments, patients, and other stakeholders to fight COVID-19 together,” IMC President Pamela Fralick in the association The annual general meeting of shareholders. "As we emerge from such a challenging time in Canada and the world, Cole’s transition from vice chairman to leadership and his commitment to cooperation and passion for our industry will continue to be a great contribution to the IMC, its members and most importantly. Canadian service."
Mr. Pinnow has more than 20 years of experience in the field of innovative drugs. Before joining Pfizer, his career began as a microbiologist at Abbott Laboratories. His experience in R&D, manufacturing, business development, and other global leadership roles provides him with a unique perspective on the challenges and opportunities facing the Canadian life sciences industry.
"The pandemic has shown us the importance of the innovative drug industry to the health and well-being of Canadians," Mr. Pinnow said. “Due to Ronnie Miller’s leadership over the past two years, our industry has never been more consistent or more focused on what we need to do. We hope to work with the government and other private sector stakeholders to build a strong and sustainable The life sciences ecosystem. An industry that will benefit all Canadians."
In his speech to members at the Annual General Meeting of Shareholders, Mr. Pinnow identified his priorities as Chairman of the Board of Directors.
"The innovative medicines department must continue to work with all our stakeholders, especially the government, to discuss what is needed to establish the life sciences department we need in Canada," Pinnow said. "There are interdependencies between different policies, such as changes in the Patent Drug Price Review Board, which will adversely affect Canada’s resilience. We must build on our success throughout the pandemic and apply our lessons learned Lessons learned. In addition to our policy challenges, we prioritize the promotion of diversity, fairness and inclusion. We must do more to ensure that our industry reflects the patients we serve and improve our solutions to healthcare The ability to make a difference."
Mr. Pinnow's term of office as chairman of the board of directors is two years.
Canadian Board of Innovative Drugs:
Cole Pinnow, President (Chairman) of Pfizer Canada ULC
Brian Heath (Vice Chairman), Vice President and General Manager of Amgen Canada
Melissa Koomey, Vice President and General Manager (Treasurer), Gilead Sciences Canada, Inc.
Jorge Bartolome, President of Janssen
Ed Dybka, General Manager of Ipsen Biopharmaceuticals Canada, Inc.
Faris El Refaie, President and General Manager of GlaxoSmithKline Canada
Jody Engel, Canada Country Manager, Knight Therapeutics Inc.
Rute Fernandes, General Manager of Takeda Canada
Alok Kanti, President and CEO of Bayer
Christian Macher, County President and General Manager of Oncology, Novartis Pharmaceuticals Canada
Ronnie Miller, President and Chief Executive Officer of Hoffman Roche Ltd.
Lisa Mullett, General Manager, Sunovion Pharmaceuticals Canada Inc.
Rhonda Pacheco, President and General Manager of Eli Lilly Canada
Tracey Ramsay, Vice President and General Manager of AbbVie
Frank Stramaglia, General Manager of Astellas Canada Pharmaceuticals
The Canadian Innovative Medicine Association is a national association that represents the voice of the Canadian innovative pharmaceutical industry. The association advocates policies that can discover, develop, and deliver innovative drugs and vaccines to improve the lives of all Canadians, and supports members in their efforts to become important partners in the Canadian healthcare system. “The association represents 48 companies that invest nearly US$1.2 billion in research and development each year, which promotes Canada’s knowledge economy and contributes US$8 billion to the Canadian economy. Under the guidance of the Code of Ethical Practice, all members are in partnership with the government. , Private payers, healthcare professionals and stakeholders in a highly ethical manner.
Erin Brophy Communications Executive Director Tel: (613) 219-6087 Email: media@imc-mnc.ca
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104765
New Delhi (Reuters)-Officials said that as U.S. Trade Representative Katherine Tai (Katherine Tai) began a two-day visit, India and the U.S. agreed to seek solutions to their differences on issues such as market access and digital trade. method. As New Delhi and Washington are arguing over a series of issues such as tariffs, the negotiators of the two countries have been working hard to reach a trade plan for more than a year. Accompanied by her deputy ambassador Sarah Bianchi, Dai proposed market access restrictions, high tariffs, unpredictable regulations and restricted digital trade between the two countries in New Delhi.
Unless you have been living under a few rocks, it is not surprising to hear that Pfizer (NYSE: PFE) is one of the leaders in the COVID-19 drug market. Between its highly successful vaccine and the due diligence development of its upcoming antiviral therapy, the company has risen to meet the moment of the pandemic. Let's take a look at four reasons why it is positioned as the best COVID growth stock on the market in the next few years.
The recent acquisition of Dicerna Pharmaceuticals makes Arrowhead Pharmaceuticals look like the next biotech company to secure a lucrative acquisition offer.
According to experimental data, a new vaccine designed to specifically target Covid to produce T cells produced a better immune response than the alternatives already used.
After Merck's Covid pill monupivir brings new hope to the fight against Covid-19, is Merck's stock worth buying? Can MRK stock be bought now?
Researchers calculated that the US government provided $2.5 billion for the development and commercialization of Moderna's COVID-19 vaccine.
On Tuesday, a federal jury found that chain pharmacy operators CVS Health Corp, Walgreens Boots Alliance Inc, and Walmart Inc had contributed to the opioid epidemic in two Ohio counties, which these two companies faced due to the U.S. drug crisis The first trial. Jurors in the Cleveland Federal Court concluded that the actions of chain pharmacies contributed to public nuisance, caused an oversupply of addictive painkillers, and transferred these opioids to the black market. U.S. District Judge Dan Polster will determine how much these companies should owe to mitigate or resolve public hazards in Lake County and Trumbull County, Ohio.
Chinese technology giant Baidu said on Monday that it has licensed its messenger RNA (mRNA) sequence algorithm to Sanofi to design vaccines and therapeutic products. This is its first such commercial transaction with a major global drugmaker. Before the pandemic, Sanofi had been one of the world's largest vaccine manufacturers, but the French company was defeated by rivals BioNTech/Pfizer and Moderna in developing mRNA vaccines against COVID-19. Sanofi stopped trials of its own mRNA COVID-19 vaccine in September, and instead focused on working with GlaxoSmithKline to bring another COVID-19 vaccine candidate to the market based on a more traditional protein-based approach.
Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced a long-term analysis of the safety and effectiveness of their COVID-19 vaccine in people aged 12 to 15 Top line results. The latest results of the Phase 3 trial indicate that the effectiveness of a two-dose series of vaccines (30 micrograms per dose) against COVID-19 is 100% during 7 days to more than four months after the second vaccination. Data from nearly 2,230 participants show that 30 cases of COVID-19 have been reported
As of 11:45 a.m. Eastern Time on Monday, Moderna's (NASDAQ: MRNA) share price has risen 5.4%. Others may be more concerned about the German government's decision to promote Moderna's booster to its citizens. In addition, the Minister of Health of Singapore publicly stated that people who initially received two doses of Pfizer-BioNTech COVID-19 vaccine should consider getting Moderna vaccine as their booster.
Oklahoma coronavirus information resources, including deaths, hospitalizations, vaccinations, and new cases.
The European Medicines Agency said it is evaluating whether to authorize Johnson & Johnson's single booster dose of COVID-19 vaccine. In a statement on Monday, the European Union's drug regulator said it is considering Johnson & Johnson's application to recommend a booster dose of Johnson & Johnson vaccine for adults 18 years and older at least two months after their first vaccination. With the surge in new coronavirus infections across Europe, EMA said it expects to make a decision on this within a few weeks.
Pfizer and BioNTech SE said on Monday that the long-term analysis of the safety and effectiveness of their COVID-19 vaccine in people aged 12 to 15 showed that the two-dose series of Pfizer-BioNTech COVID-19 vaccine (30 micrograms per dose) The effective rate of COVID-19 is 100%. The follow-up test is performed 7 days to more than four months after the second dose. The two companies stated that the adverse event profile is “basically consistent with other clinical safety data for the vaccine, and is consistent with
You have heard of fentanyl, which is a deadly drug that is 100 times stronger than morphine. Now, a more effective drug called Carfentanil, which is used to calm large animals, appears on the streets of California.
Pfizer said on Monday that its COVID-19 vaccine provided strong long-term protection against the coronavirus in a late-stage study of 12 to 15-year-olds.
On Tuesday, November 23, people in Ontario can make appointments for Pfizer COVID-19 vaccinations for children between 5 and 11 years of age.
For months, critics have been urging pharmaceutical companies to do more for the world. Now, with the proliferation of Covid-19, policymakers in the U.S. and around the world are struggling to fight for guns.
TV is flooded with advertisements about drugs that can treat everything from heartburn to constipation, erectile dysfunction, depression, and obesity.
This infection is caused by a herpes virus called cytomegalovirus (CMV) and can have significant negative effects on transplant recipients, including the loss and death of transplanted organs. The FDA said it approves Takeda's drug Livtencity for the treatment of CMV disease in patients who do not respond to available antiviral treatments.
In Peru, the cannabis-based drug Sativyl has been approved for the treatment of cancer-related pain. Sativyl produced by Verdemed is as similar as possible to Sativex produced by GW Pharmaceuticals of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and is recommended for alleviating cancer symptoms and spasticity in patients with multiple sclerosis. Among other uses, Sativyl can also relieve severe pain. The drug is considered an effective, non-addictive alternative to opioids,